- Home
- HXHX vs ENLV Comparison
HXHX vs ENLV Comparison
Compare HXHX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | ENLV |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.1M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HXHX | ENLV |
|---|---|---|
| Price | $0.19 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.19 |
| 52 Week High | $1.36 | $7.64 |
Technical Indicators
Market Signals| Indicator | HXHX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 20.09 | 18.86 |
| Support Level | N/A | N/A |
| Resistance Level | $0.56 | $1.26 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 3.75 | 2.48 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is a China-based logistics company engaged in temperature-controlled transportation and urban delivery services. The company provides cold chain logistics, freight forwarding, and related transportation services for goods, including new energy materials, electronic products, pharmaceuticals, meat, fruits, and vegetables. Its principal revenue streams are temperature-controlled truckload services and urban delivery services.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.